secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2021-07-19T23:59:59+00:00
Accession:  0001140361-21-024792
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics appoints Jay Sial as Chief Administrative Officer effective July 15, 2021
--------------------------------------------------------------------------------

- Mr. Sial receives $350,000 base salary and annual bonus eligibility up to 35% of base.
- Equity grant of 71,000 stock options and 35,700 RSUs, each vesting over four years.
- Severance provides 9 months of base salary and COBRA; 12 months if near a change in control.
- Previously CFO at Aspen Neurosciences and University of California Irvine Health.
- Equity awards are inducement grants approved by compensation committee without stockholder vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036121024792/0001140361-21-024792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036121024792/brhc10027031_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-21-024792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer